#ASH18: Regeneron's bispecific REGN1979 offers eye-catching 80% CR rate in follicular lymphoma, spurring swift shift to pivotal study
As one of the world’s top — and certainly best paid — antibody drug developers, Regeneron’s George Yancopoulos tends to attract a considerable amount of attention when he gets excited by one of his clinical projects. And today you’ll find him eagerly touting a bispecific therapy that the R&D chief has sky-high hopes for.
Evidently with good reason.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.